Close

Production & Manufacturing

Tiziana announces agreement with STC Biologics for manufacturing of TZLS-501

Tiziana Life Sciences plc, a clinical stage biotechnology company developing targeted drugs for cancer, inflammatory diseases and COVID-19, announces the execution of an agreement with STC Biologics, Inc. for GMP manufacturing of TZLS-501, an anti-IL-6 receptor (anti-IL-6R) monoclonal antibody...

Cytiva upgrades Massachusetts contract biomanufacturing site with increased capacity and automation technologies

Cytiva, formerly part of GE Healthcare Life Sciences, is celebrating the completion of an extensive renovation to its Fast Trak cGMP contract biomanufacturing and process development site in Marlborough, Massachusetts, USA. The upgraded facility is 60,000 square feet (5,600...

Gemini Bio opens new manufacturing facility in West Sacramento, California

Gemini Bioproducts, LLC, a leading supplier of cell culture reagents and a portfolio company of BelHealth Investment Partners, LLC, a New York-based healthcare private equity firm,  announced the opening of a new, state-of-the-art manufacturing facility in West Sacramento, California. Gemini...

Catalent Signs Agreement with AstraZeneca to Manufacture COVID-19 Vaccine Candidate

Catalent, Inc. , the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, announced that Catalent Biologics will provide vial filling and packaging capacity to AstraZeneca...

GSK partners with Samsung Biologics to secure additional manufacturing capacity for innovative biopharmaceutical portfolio

GlaxoSmithKline and Samsung Biologics have entered into a partnership to provide GSK with additional capacity to manufacture and supply GSK’s innovative biopharmaceutical therapies. Under the terms of the agreement, Samsung Biologics will provide GSK with additional capacity for large-scale biopharmaceutical...

Recipharm secures supply of drug substance and commences manufacture of chloroquine phosphate

Recipharm, a leading contract development and manufacturing organisation (CDMO), has now secured supply of the active pharmaceutical ingredient (API) chloroquine phosphate for its drug Klorokinfosfat RPH Pharma and commenced manufacture of the product. The move comes following reports that chloroquine...

Cytovance and Akshaya Bio Announce Collaboration Agreement of Therapeutics for Treatment of Coronavirus and Hepatitis B Virus

Cytovance Biologics, a contract development and manufacturing organization (CDMO) and a subsidiary of the Shenzhen Hepalink Pharmaceutical Group Co., Ltd., has entered into a collaboration agreement with Akshaya Bio, a Canadian development stage biotechnology company to provide rapid access...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read